

# Chronic Myelocytic Leukemia (CML) - Market Insight, Epidemiology and Market Forecast - 2028

<https://marketpublishers.com/r/C18FEE85BB4EN.html>

Date: January 2019

Pages: 100

Price: US\$ 6,250.00 (Single User License)

ID: C18FEE85BB4EN

## Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Chronic Myelocytic Leukemia (CML) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Chronic Myelocytic Leukemia (CML) epidemiology and market outlook for the 7MM.

## MARKETS COVERED

United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2016-2028

Chronic Myelocytic Leukemia (CML) Understanding and Treatment Algorithm

The market report provides the overview of the Chronic Myelocytic Leukemia (CML) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Chronic Myelocytic Leukemia (CML) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases

and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Chronic Myelocytic Leukemia (CML) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

#### Chronic Myelocytic Leukemia (CML) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

#### Chronic Myelocytic Leukemia (CML) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Chronic Myelocytic Leukemia (CML) market.

#### Chronic Myelocytic Leukemia (CML) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

#### Chronic Myelocytic Leukemia (CML) Report Insights

##### Patient Population in Chronic Myelocytic Leukemia (CML)

##### Therapeutic Approaches in Chronic Myelocytic Leukemia (CML)

Chronic Myelocytic Leukemia (CML) Pipeline Analysis

Chronic Myelocytic Leukemia (CML) Market Size and Trends

Chronic Myelocytic Leukemia (CML) Market Opportunities

Impact of upcoming Therapies in Chronic Myelocytic Leukemia (CML)

## Chronic Myelocytic Leukemia (CML) Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

## Chronic Myelocytic Leukemia (CML) Report Assessment

Current Treatment Practices in Chronic Myelocytic Leukemia (CML)

Unmet Needs in Chronic Myelocytic Leukemia (CML)

Market Attractiveness

Market Drivers and Barriers

## KEY BENEFITS

The report will help to develop Business Strategies by understanding the trends shaping and driving the Chronic Myelocytic Leukemia (CML) market

Organize sales and marketing efforts by identifying the best opportunities for Chronic Myelocytic Leukemia (CML) market

To understand the future market competition in the Chronic Myelocytic Leukemia (CML) market.

## Contents

### **1. REPORT INTRODUCTION**

### **2. CHRONIC MYELOCYTIC LEUKEMIA (CML) MARKET OVERVIEW AT A GLANCE**

2.1. Market Share Distribution of Chronic Myelocytic Leukemia (CML) in 2016

2.2. Market Share Distribution of Chronic Myelocytic Leukemia (CML) in 2028

### **3. DISEASE BACKGROUND AND OVERVIEW: CHRONIC MYELOCYTIC LEUKEMIA (CML)**

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

### **4. EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM

4.3. Total Prevalent Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM – By Countries

### **5. EPIDEMIOLOGY OF CHRONIC MYELOCYTIC LEUKEMIA (CML) BY COUNTRIES**

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.1.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.1.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.1.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.1.6. Treatable Cases of the Chronic Myelocytic Leukemia (CML)

5.2. EU5

5.3. Assumptions and Rationale

## 5.4. Germany

### 5.4.1. Assumptions and Rationale

### 5.4.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

### 5.4.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

### 5.4.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

### 5.4.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

### 5.4.6. Treatable Cases of the Chronic Myelocytic Leukemia (CML)

## 5.5. France

### 5.5.1. Assumptions and Rationale

### 5.5.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

### 5.5.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

### 5.5.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

### 5.5.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

### 5.5.6. Treatable Cases of the Chronic Myelocytic Leukemia (CML)

## 5.6. Italy

### 5.6.1. Assumptions and Rationale

### 5.6.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

### 5.6.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

### 5.6.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

### 5.6.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

### 5.6.6. Treatable Cases of the Chronic Myelocytic Leukemia (CML)

## 5.7. Spain

### 5.7.1. Assumptions and Rationale

### 5.7.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

### 5.7.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

### 5.7.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

### 5.7.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

### 5.7.6. Treatable Cases of the Chronic Myelocytic Leukemia (CML)

## 5.8. United Kingdom

### 5.8.1. Assumptions and Rationale

### 5.8.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

### 5.8.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

### 5.8.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

### 5.8.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

### 5.8.6. Treatable Cases of the Chronic Myelocytic Leukemia (CML)

## 5.9. Japan

### 5.9.1. Assumptions and Rationale

### 5.9.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

### 5.9.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.9.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.9.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.9.6. Treatable Cases of the Chronic Myelocytic Leukemia (CML)

## **6. CURRENT TREATMENT & MEDICAL PRACTICES**

6.1. Treatment Algorithm

6.2. Treatment Guidelines

## **7. UNMET NEEDS OF THE CHRONIC MYELOCYTIC LEUKEMIA (CML)**

## **8. MARKETED THERAPIES**

8.1. Drug A: Company

8.1.1. Drug Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Advantages & Disadvantages

8.1.5. Product Profile

8.2. Drug B: Company

8.2.1. Drug Description

8.2.2. Mechanism of Action

8.2.3. Regulatory Milestones

8.2.4. Advantages & Disadvantages

8.2.5. Product Profile

## **9. PIPELINE THERAPIES – AT A GLANCE**

## **10. KEY CROSS COMPETITION**

## **11. EMERGING THERAPIES FOR CHRONIC MYELOCYTIC LEUKEMIA (CML)**

11.1. Drug C: Company

11.1.1. Drug Description

11.1.2. Clinical Trials Details

11.1.3. Safety and Efficacy Profile

11.1.4. Advantages & Disadvantages

11.1.5. Pipeline Development Activities

11.1.6. Product Profile

## 11.2. Drug D: Company

### 11.2.1. Drug Description

### 11.2.2. Clinical Trials Details

### 11.2.3. Safety and Efficacy Profile

### 11.2.4. Advantages & Disadvantages

### 11.2.5. Pipeline Development Activities

### 11.2.6. Product Profile

## 12. CHRONIC MYELOCYTIC LEUKEMIA (CML): 7MM MARKET ANALYSIS

### 12.1. 7MM Market Size of Chronic Myelocytic Leukemia (CML)

### 12.2. 7MM Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML)

### 12.3. 7MM Market Sales of Chronic Myelocytic Leukemia (CML) by Products

## 13. CHRONIC MYELOCYTIC LEUKEMIA (CML): COUNTRY-WISE MARKET ANALYSIS

### 13.1. United States

#### 13.1.1. Market Size of Chronic Myelocytic Leukemia (CML) in United States

#### 13.1.2. Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML) in United States

#### 13.1.3. Market Sales of Chronic Myelocytic Leukemia (CML) by Products in United States

#### 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

### 13.2. EU-5

#### 13.2.1. Germany

##### 13.2.1.1. Market Size of Chronic Myelocytic Leukemia (CML) in Germany

##### 13.2.1.2. Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML) in Germany

##### 13.2.1.3. Market Sales of Chronic Myelocytic Leukemia (CML) by Products in Germany

##### 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

#### 13.2.2. France

##### 13.2.2.1. Market Size of Chronic Myelocytic Leukemia (CML) in France

##### 13.2.2.2. Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML) in France

##### 13.2.2.3. Market Sales of Chronic Myelocytic Leukemia (CML) by Products in France

##### 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market



### 13.2.3. Italy

13.2.3.1. Market Size of Chronic Myelocytic Leukemia (CML) in Italy

13.2.3.2. Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML) in Italy

13.2.3.3. Market Sales of Chronic Myelocytic Leukemia (CML) by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

### 13.2.4. Spain

13.2.4.1. Market Size of Chronic Myelocytic Leukemia (CML) in Spain

13.2.4.2. Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML) in Spain

13.2.4.3. Market Sales of Chronic Myelocytic Leukemia (CML) by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

### 13.2.5. United Kingdom

13.2.5.1. Market Size of Chronic Myelocytic Leukemia (CML) in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML) in United Kingdom

13.2.5.3. Market Sales of Chronic Myelocytic Leukemia (CML) by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

### 13.3. Japan

13.3.1. Market Size of Chronic Myelocytic Leukemia (CML) in Japan

13.3.2. Percentage Share of drugs marketed for Chronic Myelocytic Leukemia (CML) in Japan

13.3.3. Market Sales of Chronic Myelocytic Leukemia (CML) by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

## 14. MARKET DRIVERS

## 15. MARKET BARRIERS

## 16. APPENDIX

## 17. REPORT METHODOLOGY

### 17.1. Sources

## 18. DELVEINSIGHT CAPABILITIES

## 19. DISCLAIMER

## 20. ABOUT DELVEINSIGHT

Indication Specific

## List Of Tables

### LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM

Table 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 7: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 11: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 12: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 14: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 15: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 16: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 17: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy

(2016-2028)

Table 19: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Table 20: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Table 21: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Table 22: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Table 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Table 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Table 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Table 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Table 27: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Table 28: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Table 29: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Table 30: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Table 31: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Table 32: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Table 33: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Table 34: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Table 35: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Table 36: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Table 37: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41: 7MM- Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Table 42: 7MM- Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 43: 7MM- Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Table 45: United States-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Table 48: Germany-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Table 51: France-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Table 54: Italy-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Table 57: Spain-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM  
(2016-2028)

Table 60:UK-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD  
MM (2016-2028)

Table 61:UK-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD  
MM (2016-2028)

Table 62: Japan-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM  
(2016-2028)

Table 63: Japan-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in  
USD MM (2016-2028)

Table 64: Japan-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in  
USD MM (2016-2028)

## List Of Figures

### LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 7: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 12: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 15: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 16: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 17: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy

(2016-2028)

Figure 19: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Figure 20: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Figure 21: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Figure 22: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Italy  
(2016-2028)

Figure 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Figure 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Figure 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Figure 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Figure 27: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Spain  
(2016-2028)

Figure 28: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Figure 29: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Figure 30: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Figure 31: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Figure 32: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in UK  
(2016-2028)

Figure 33: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in  
Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Figure 35: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Figure 36: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)

Figure 37: Treatable Cases of the Chronic Myelocytic Leukemia (CML) in Japan  
(2016-2028)



Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41: 7MM- Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Figure 42: 7MM- Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 43: 7MM- Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Figure 45: United States-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Figure 48: Germany-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Figure 51: France-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Figure 54: Italy-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM (2016-2028)

Figure 57: Spain-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM  
(2016-2028)

Figure 60:UK-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in USD  
MM (2016-2028)

Figure 61:UK-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in  
USD MM (2016-2028)

Figure 62: Japan-Market Size of Chronic Myelocytic Leukemia (CML) in USD MM  
(2016-2028)

Figure 63: Japan-Market Share Chronic Myelocytic Leukemia (CML) by Therapies in  
USD MM (2016-2028)

Figure 64: Japan-Market Sales of Chronic Myelocytic Leukemia (CML) by Therapies in  
USD MM (2016-2028)

## I would like to order

Product name: Chronic Myelocytic Leukemia (CML) - Market Insight, Epidemiology and Market Forecast - 2028

Product link: <https://marketpublishers.com/r/C18FEE85BB4EN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C18FEE85BB4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

